Day: July 30, 2020
DUBLIN, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Giga-tronics Incorporated (OTCQB:GIGA) will release results for the first quarter ended June 27, 2020 on Thursday August 6, 2020 after the close of trading on the OTCQB Market.Also on August 6, 2020, Giga-tronics will host a conference call at 4:30 p.m. EDT to discuss the results and provide an update on Company operations.To participate in the call, dial: (888) 517-2470 or (630) 827-6818 and enter PIN Code 6822983#. It is recommended that you call in five to ten minutes prior to the start time. You may also listen to the call via the Giga-tronics website at www.gigatronics.com.A replay of the call will be available later on the Giga-tronics website under “Investor Relations”. This conference call will reflect management views as of August 6, 2020 only.Giga-tronics produces electronic...
Virbac: bilan semestriel du contrat de liquidité au 30 juin 2020
Written by Customer Service on . Posted in Public Companies.
VIRBAC
UPDATE — EHang to Expand Production Facility for Autonomous Aerial Vehicles
Written by Customer Service on . Posted in Public Companies.
GUANGZHOU, China, July 30, 2020 (GLOBE NEWSWIRE) — EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company, today announced it will build a new AAV production facility in Yunfu city in Guangdong, China with a planned initial annual capacity of 600 units and an RMB42 million (approx. US$6 million) investment supported by the local government in the facility. The EHang Yunfu facility is aimed to be established as an industry-leading AAV production center, including an R&D facility for air mobility solutions and a training center for operations and technical talents.The Deputy Mayor of Yunfu city, Donghong Shi attended the launch ceremony and commented that the Yunfu city government welcomes and fully supports the world’s leading high-tech...
Capitala Group Announces New Hires as it Expands its Underwriting and Investor Relations Teams
Written by Customer Service on . Posted in Public Companies.
CHARLOTTE, N.C., July 30, 2020 (GLOBE NEWSWIRE) — Capitala Group (“Capitala”), a leading provider of capital to lower middle market companies, announced today it has expanded its underwriting and investor relations teams. Stuart McGoogan is joining as Investor Relations Associate, while Nico Mancuso and Kevin Mansfield will serve on the underwriting team as Associate and Analyst respectively.“We are playing a vital role in assisting the middle-market companies of which we’ve invested best navigate the market uncertainty, and I am extremely proud of the hard work Capitala has done in this regard,” said Joe Alala, Chairman and Chief Executive Officer of Capitala. “To that end, we continue to expand our team and services across our entire organization.”Stuart McGoogan previously held various client service roles at Barings (fka Babson...
Datametrex Initiates OTCQB Application
Written by Customer Service on . Posted in Public Companies.
TORONTO, July 30, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (“Datametrex” or the “Company“) (TSXV: DM, FSE: D4G, OTC: DTMXF) announces that it has commenced the process to have the Company’s common shares upgraded and quoted on the OTCQB® Market exchange in the United States.The Company’s Canadian legal counsel, McMillan LLP, will be acting as Principal American Liaison (“PAL”) in assisting the Company through the U.S. listing application process. Subject to fulfilling various regulatory requirements and completion of due diligence, the Company believes the process should take no more than three months.Moving to the OTCQB® in the United States will provide existing shareholders with an additional trading platform to the TSX Venture Exchange in addition to introducing the Company to a broader range of...
Fidelity D & D Bancorp, Inc. Announces Third Quarter Dividend and Reports Second Quarter 2020 Financial Results
Written by Customer Service on . Posted in Public Companies.
DUNMORE, PA , July 30, 2020 (GLOBE NEWSWIRE) — Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC) and its banking subsidiary The Fidelity Deposit and Discount Bank, announced its most recent dividend declaration and unaudited, consolidated financial results for the three and six month periods ended June 30, 2020.Dividend DeclaredThe Board of Directors of Fidelity D & D Bancorp, Inc. (the “Company”) announced their declaration of the Company’s third quarter dividend of $0.28 per share. The dividend is payable September 10, 2020 to shareholders of record at the close of business on August 20, 2020.Unaudited Financial InformationNet income for the quarter ended June 30, 2020 was $0.3 million, or $0.05 diluted earnings per share, compared to $3.0 million, or $0.79 diluted earnings per share, for the quarter ended June 30, 2019. ...
Correction: AB Klaipėdos nafta preliminary revenue for the June 2020
Written by Customer Service on . Posted in Public Companies.
Correction: Announcing the total preliminary revenue figures for 2020 January-June and January-May mistake has been made – commercial LNG activity segment has not been included in total amount. Corrections as follows:Total preliminary sales revenue of the Company for the January-June 2020 amount to EUR 39.4 million and is lower by 23.0 per cent compared to the same period of 2019 – EUR 51.2 million.Preliminary revenue of the Company, EUR million:Total preliminary sales revenue of the Company for the January-May 2020 amount to EUR 33.4 million and is lower by 21.8 per cent compared to the same period of 2019 – EUR 42.7 million.Preliminary revenue of the Company, EUR million:Jonas Lenkšas, Chief Financial Officer, +370 694 80594.
Correction: AB „Klaipėdos nafta“ 2020 metų birželio mėn. preliminarios veiklos pajamos
Written by Customer Service on . Posted in Public Companies.
Patikslinimas: Skelbiant bendras Bendrovės pardavimo pajamas už 2020 m. sausio-birželio mėn. ir sausio-gegužės mėn. buvo padarytos klaidos į bendrą („iš viso“) pajamų sumą neįtraukus komercinės SGD veiklos segmento. Patikslinta informacija pateikta žemiau:Iš viso Bendrovės preliminarios 2020 m. sausio-birželio mėn. pardavimo pajamos sudaro 39,4 mln. eurų ir yra 23,0 proc. mažesnės nei 2019 m. atitinkamu laikotarpiu (51,2 mln. eurų).Preliminarios Bendrovės pajamos, mln. EUR:Iš viso Bendrovės preliminarios 2020 m. sausio-gegužės mėn. pardavimo pajamos sudaro 33,4 mln. eurų ir yra 21,8 proc. mažesnės nei 2019 m. atitinkamu laikotarpiu (42,7 mln. eurų).Preliminarios Bendrovės pajamos, mln. EUR:Jonas Lenkšas, Finansų direktorius, tel. +370 694 80594.
SmartCentres 2020 Second Quarter Results and Conference Call
Written by Customer Service on . Posted in Public Companies.
TORONTO, July 30, 2020 (GLOBE NEWSWIRE) — SmartCentres Real Estate Investment Trust (“SmartCentres”) (TSX: SRU.UN) announced today that it will issue its financial results for the three and six months ending June 30, 2020 on Wednesday, August 5, 2020.SmartCentres will hold a conference call on Thursday, August 6, 2020 at 2:00 p.m. (ET). Participating on the call will be members of SmartCentres’ senior management.Investors are invited to access the call by dialing 1-855-353-9183 and then keying in the participant access code 93397#. You will be required to identify yourself and the organization on whose behalf you are participating.A recording of this call will be made available Thursday, August 6, 2020 beginning at 8:30 p.m. (ET) through to 8:30 p.m. (ET) on Thursday, August 13, 2020. To access the recording, please call 1-855-201-2300,...
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
Written by Customer Service on . Posted in Public Companies.
SEATTLE, July 30, 2020 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announces interim findings following 18 months of an Expanded Access (or “compassionate use”) single-patient study of Atossa’s Endoxifen. To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and the treatment has been well tolerated, including an absence of typically seen vasomotor symptoms (for example, night sweats and hot flashes).The study results show that treatment with Atossa’s...